GRAFTON DBM

K051195 · Osteotech, Inc. · MBP · Dec 16, 2005 · Orthopedic

Device Facts

• Record ID: K051195
• Device Name: GRAFTON DBM
• Applicant: Osteotech, Inc.
• Product Code: MBP · Orthopedic
• Decision Date: Dec 16, 2005
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3045
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

GRAFTON® DBM is intended for use as a bone graft extender, bone graft substitute, and bone void filler in bony voids or gaps of the skeletal system (i.e., spine, pelvis and extremities); created defects or defects created by trauma to the bone. In and is resorbed/remodeled and is replaced by host bone during the healing process.

Device Story

GRAFTON® DBM is a human bone allograft product consisting of demineralized bone matrix (DBM) and an inert carrier; used as a bone void filler, graft extender, or substitute. Provided ready-to-use in various physical forms (gel, flex, putty, matrix, crunch, orthoblend) to allow for molding, cutting, or manipulation by surgeons during orthopedic or spinal procedures. The device is osteoconductive and osteoinductive; it fills bony voids or gaps, providing stability to the skeletal structure while being resorbed and remodeled into host bone during the healing process. The product undergoes a proprietary viral inactivation process to reduce disease transmission risk. It is intended for prescription use by clinicians to treat skeletal defects.

Clinical Evidence

Performance supported by animal and human studies. Osteoinductivity is confirmed via a validated athymic rat assay, scoring bone formation at 28 days. Viral inactivation efficacy validated against HIV-1, hepatitis B, hepatitis C, and polio viruses. Clinical performance is supported by existing data demonstrating successful outcomes comparable to predicate devices.

Technological Characteristics

Human demineralized bone matrix (DBM) allograft with inert carrier. Physical forms include gel, flex, putty, matrix, crunch, and orthoblend. Osteoconductive and osteoinductive properties. Proprietary viral inactivation process for DBM component. Resorbable bone void filler. Class II device.

Indications for Use

Indicated for use as a bone graft extender, bone graft substitute, and bone void filler in surgically created or trauma-induced bony voids or gaps of the skeletal system, including the spine, pelvis, and extremities, to provide stability to the bony structure.

Regulatory Classification

Identification

A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

Submission Summary (Full Text)

{0}------------------------------------------------

K051195

## DEC 1 6 2005

## XII. 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

December 15, 2005

- 1. Submission Applicant & Correspondent:

| Name: | Osteotech, Inc. |
|-----------------|-------------------------------------|
| Address: | 51 James Way<br>Eatontown, NJ 07724 |
| Phone No.: | [phone] |
| Contact Person: | Chris Talbot |

- 2. Name of Product:

| Trade/Proprietary/Model Name: | GRAFTON® DBM (Gel, Flex, Putty, Matrix<br>Crunch, Orthoblend) |
|-------------------------------|---------------------------------------------------------------|
| Common or Usual Name: | Demineralized Bone Matrix Allograft |
| Classification Name: | Resorbable Bone Void Filler |

- 3. Devices to Which New Product is Substantially Equivalent:
GRAFTON® DBM is substantially equivalent, for the purpose of this 510(k), to other devices that have received 510(k) clearance for similar indications for use.

- 4. Device Description:
GRAFTON®DBM is a human bone allograft product containing human demineralized bone matrix (DBM) and an inert additive for intraoperative deminerallizon bone matinr use in filling bony voids or gaps of the skeletal system nanding. It is internativility of the bony structure. GRAFTON® DBM is provided ready-to-use in various physical forms and in various package sizes by volume or dimension.

GRAFTON® DBM is a demineralized bone product that is osteoconductive as well as osteoinductive in an athymic rat assay. It is prepared via a proprietary woll as betterfuler of Osteotech, Inc. that has been validated to consistently produce DBM that is osteoinductive in an athymic rat assay. Product and process consistency are confirmed via ongoing testing of GRAFTON® DBM product for osteoinductivity in this validated athymic rat assay utilizing a missica product for occomise , a to score bone formation at 28 days*. This bone five point linear boals (0) 7/2/07/27TON® DBM in this athymic rat surrogate assay should not be interpreted as a predictor of clinical performance.

*Edwards, J.T., PhD, Diegmann, M.H., MS, Scarborough, N.L., PhD.: Osteoinduction of Human Edwards, a. F., F.B., Diogramm, Rating in a Rat Model. Clinical Orthopaedics, December, 1998, Volume 357.

{1}------------------------------------------------

- 5. Intended Use/Indications
GRAFTON® DBM is intended for use as a bone graft extender, bone graft GRAFTON - DDM is interiaculation as a sor gaps of the skeletal system (i.e., substitute, and bone vold micr in bony volto the stability of the bony structure. spine, peris and Oxtromitios); created defects or defects or defects created by The volus of gaps may be bargiously on the bone. In and is resorbed/remodeled and is treplaced by host bone during the healing process

- 6. Technical Comparison
GRAFTON® DBM is substantially equivalent to one or more of the predicate devices with respect to materials in that it contains human demineralized bone devices with respect to matemals in the enditive or carrier. It is provided readymatin (DDM) in a roonbable non of that can be molded, manipulated or cut to-use in various malicablomoxible room or sizes. It is implanted in this malleable/flexible state.

- 7. Performance Data
The results of studies in animals and humans showed that GRAFTON® DBM THE TESGIRS of Station ell as, if not better than, predicate devices and/or performs at load. as not animal and clinical data exist that support the successful performance of GRAFTON® DBM.

- 8. Viral Inactivation
The DBM in GRAFTON® DBM is produced by a proprietary production process that has been validated to inactivate viruses including: HIV-1; hepatitis B virus (duck hepatitis virus as model); hepatitis C virus (bovine diarrhea virus as (adok hopatitio virus as mous , This process is used to further reduce the risk of model), OMY, and Pollo the use of this product beyond the protection provided by donor testing and screening procedures.

The process used to produce the non-demineralized cancellous bone chips in Grafton® DBM Orthoblend does not afford the same degree of viral inactivation as the process used to produce the DBM. However, the risk of disease as the prooooo used to proac component remains low due to multiple safeguards that are rigorously employed, including donor screening, laboratory testing and material processing.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes entwined around it. The logo also includes the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES. USA" arranged in a circular fashion around the caduceus symbol. The logo is black and white.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 1 6 2005

Mr. Christopher Talbot Director, Regulatory Affairs Osteotech, Inc. 51 James Way Eatontown, NJ 07724

Re: K051195

GRAFTON ® DBM Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler devices Regulatory Class: Class II Product Code: MBP, MQV Dated: September 16, 2005 Received: September 19, 2005

Dear Mr. Talbot:

We have reviewed your Section 510(k) premarket notification of intent to market the device we have reviewed your becater on edited is substantially equivalent (for the itelered above and have acteriminoure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device mendments, or to devices that have been reclassified in accordance with the provisions of Amendinens, or to dovroes that in i e Act (Act) that do not require approval of a premarket the rederal I ood, Drag, and Commonsy, therefore, market the device, subject to the general approvin uppheation (The Act. The general controls provisions of the Act include controls provideons of the sixtration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III 17 your device to such additional controls. Existing major regulations affecting (1 Nr.), it may of subject to tack adde of Federal Regulations, Title 21, Parts 800 to 898. In your device can be found in the Cours nouncements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not I least be advised that 1 DT of issualise on that your device complies with other requirements mean that I Dr I has made statutes and regulations administered by other Federal agencies.

{3}------------------------------------------------

Page 2 – Mr. Christopher Talbot

You must comply with all the Act's requirements, including, but not limited to: registration You must comply with an the Act s requirements int 801); good manufacturing practice
and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing (21 CFR Par and listing (21 CFR Part 807), labeling (21 CFR Part 807), Books (21 CFR Part 820); and if
requirements as set forth in the quality systems (QS) regulation (21 CFR Parts A requirements as set form in the quality systems (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section This letter will anow you to ocgin marketing your es substantial equivalence of your device and thus ว I 0(K) premarket notification: The 1 DA minute of our device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Patt 801), If you desire specific advice for your device on our labor, also, please note the regulation please contact the Office of Comphance at (210) = 10 = 10 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 may obtain other general information on your responsibilities under the Act from the may obtain of Small Manufacturers, International and Consumer Assistance at its toll-free Division of Sman Manaka [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely vours.

Mark N. Melkerson. Acting Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Indications for Use – Statement 111.

510(k) Number (if known): K051195

Device Name: GRAFTON ®DBM

Indications for Use:

GRAFTON® DBM is intended for use as a bone graft extender, bone graft GRAFTON "DDM is intended for acc access of the skeletal system.
substitute, and bone void filler in bony voids or gaps of the first hany Substitute, and bone vold mior in bony volume to the stability of the bony (I.E., Spine, perios and Oxtronikas) he surgically created defects or defects Structure. The volue of gapo the bone. GRAFTON® DBM is created by tradmationing to the bel by host bone during the healing process.

Prescription Use__X (Per 21 CFR 801.109) OR

Over-The-Counter Use (Optional Format 1-2-96)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

bare Bonem for mxm
Title: Sign Off

ral. Restorative, Division of Get and Neurological Devices

**510(k) Number** K051195